GlaxoSmithKline announced that it is halting the phase III trial of a MAGE-A3 therapeutic vaccine for non–small cell lung cancer after deciding it will not be possible to find a subgroup of patients who might benefit. This comes less than 2 weeks after the company had said that the vaccine was not helping patients overall, but that they would continue to look for improvements among subgroups of patients based on genetic profiles.
A second trial evaluating the vaccine in melanoma patients is continuing to investigate effects within subgroups of patients, and final results are expected in 2015.
Read more here.